Pubblicazioni

Reduced-Intensity delayed intensification in standard-Risk pediatric acute lymphoblastic leukemia defined by undetectable minimal residual disease: Results of an international randomized trial (AIEOP-BFM ALL 2000)

2018 - JOURNAL OF CLINICAL ONCOLOGY

Schrappe, M.; Bleckmann, K.; Zimmermann, M.; Biondi, A.; Moricke, A.; Locatelli, F.; Cario, G.; Rizzari, C.; Attarbaschi, A.; Valsecchi, M. G.; Bartram, C. R.; Barisone, E.; Niggli, F.; Niemeyer, C.; Testi, A. M.; Mann, G.; Ziino, O.; Schafer, B.; Panzer-Grumayer, R.; Beier, R.; Parasole, R.; Gohring, G.; Ludwig, W. -D.; Casale, F.; Schlegel, P. -G.; Basso, G.; Conter, V.

Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy. a âreal lifeâ retrospective analysis of progression-free (PFS) and overall survival (OS) according to duration of androgen deprivation therapy

2016 - JOURNAL OF CLINICAL ONCOLOGY

Maria Agnese, Fabbri; Marchetti, Paolo; Enrico, Cortesi; Daniele, Santini; Teresa, Gamucci; Francesco, Angelini; Isabella, Sperduti; Flavia, Longo; Arianna, Pellegrino; Milano, Annalisa; Silvia, Quadrini; Ml, Mancini; Francesca, Primi; Fabrizio, Nelli; Raffaele, Ratta; Enzo, Ruggeri

Pubblicazioni

Reduced-Intensity delayed intensification in standard-Risk pediatric acute lymphoblastic leukemia defined by undetectable minimal residual disease: Results of an international randomized trial (AIEOP-BFM ALL 2000)

Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy. a âreal lifeâ retrospective analysis of progression-free (PFS) and overall survival (OS) according to duration of androgen deprivation therapy

Abiraterone acetate in metastatic castration-resistant prostate cancer after chemotherapy. a âreal lifeâ retrospective analysis of progression-free (PFS) and overall survival (OS) according to duration of androgen deprivation therapy